Figure 4From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome Recurrence-free survival (RFS) in high-risk patients with imatinib adjuvant therapy. (A) RFS by mitosis count > 10/50 HPF in patients with imatinib adjuvant therapy. (B) RFS by serosal invasion in patients with imatinib adjuvant therapy.Back to article page